Novakand Pharma to hold Extraordinary General Meeting to decide on future business direction – Comments from the board of directors
Novakand’s Board of Directors proposes new business direction and relisting to be presented at Extraordinary General Meeting
The board evaluates Novakand Pharma’s options after the decision not to execute the planned reverse take over of SVF Vaccines
Novakand Pharma applies for Nasdaq’s approval of continued listing of the combined company post a completed reverse takeover with SVF Vaccines
Interim Report Third Quarter 2025, July 1 – September 30 Novakand Pharma AB (publ.), org.no. 556806-8851
